SMMT
Summit Therapeutics Inc. · Healthcare
18.69
3.56%(-0.69)
Prev. Close19.16
2.51%(+0.47)
Pre-marketLast Updated: — ET
52W L: $13.8352W H: $36.91
$18.78
CHG+4.07 (+27.67%)
H$19.84
L$14.50
VOL38M
SMMT (1h)
Summit Therapeutics Inc. · Healthcare
Anand Bhaskar
officer: Chief Accounting Officer
30,000 SH @ $18.83
2026-01-08
Zanganeh Mahkam
director, 10 percent owner, officer: Co-Chief Executive Officer
11,232 SH @ $17.52
2026-01-02
DUGGAN ROBERT W
director, 10 percent owner, officer: Co-Chief Executive Officer
11,232 SH @ $17.52
2026-01-02
Booth Robert F.
director
35,000 SH @ $17.52
2026-01-02
Booth Robert F.
director
7,180 SH @ $17.52
2026-01-02
Xia Yu
director
35,000 SH @ $17.52
2026-01-02
Huber Jeff
director
35,000 SH @ $17.52
2026-01-02
Huber Jeff
director
9,885 SH @ $17.52
2026-01-02
Aberdeen Group plc lowered its stake in Summit Therapeutics PLC (NASDAQ: SMMT) by 18.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 927,171 shares of the company's stock after selling 212,359 shares during the period. Aberdeen
Summit Therapeutics (NASDAQ: SMMT - Get Free Report) and Cosmos Health (NASDAQ: COSM - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Analyst Ratings This is a summary of current
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and.
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript
Citigroup Inc. increased its holdings in Summit Therapeutics PLC (NASDAQ: SMMT) by 41.1% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 159,873 shares of the company's stock after buying an additional 46,535 shares during the quarter. Citigroup Inc.'s holdings in Summit Therapeutics were worth
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript